Sign In
Buy ABBV
$227.23
+2.30 (+1.02%)
At Close: Jun 05, 2026
5 Dividend Aristocrats Primed For a Big 2024
12:44pm, Sunday, 07'th Jan 2024
The company develops and markets drugs in areas such as: Immunology Virology Renal disease Dyslipidemia Neuroscience One of the biggest concerns with AbbVie is what might eventually happen with the an
3 Boneheaded Investing Mistakes I Pledge Not to Make (Again) in 2024 and Beyond
08:30am, Sunday, 07'th Jan 2024
Sending good money after bad can lead to big losses. Bubbles can look the most appealing to invest in right before they pop.
Is AbbVie Stock a Buy Now?
07:33am, Sunday, 07'th Jan 2024
AbbVie is treading water with sales as Humira fades. But it could mean several years without meaningful earnings growth.
3 Magnificent High-Yield Dividend Stocks to Buy in 2024
07:50am, Saturday, 06'th Jan 2024
AbbVie is a Dividend King that should soon return to growth. Bristol Myers Squibb boasts an impressive streak of dividend hikes and a promising pipeline.
How I Beat The Market Again In 2023
06:07pm, Friday, 05'th Jan 2024
I express frustration with the constant negativity surrounding the idea that beating the market is impossible for the average investor. I share my personal success in beating the market in 2023, with
Will AbbVie (ABBV) Beat Estimates Again in Its Next Earnings Report?
01:32pm, Friday, 05'th Jan 2024
AbbVie (ABBV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
AbbVie: Still Expensive Despite The Great M&A Acumen
09:00am, Friday, 05'th Jan 2024
ABBV's Humira erosion has been well balanced by the robust growth reported by Skyrizi and Rinvoq, implying its ability to maintain a stable top/ bottom line performance ahead. The management has also
AbbVie shares higher following ‘overdone' reaction to CVS move to replace top-selling arthritis drug
02:06pm, Thursday, 04'th Jan 2024
Abbvie Inc (NYSE:ABBV) shares recovered in the early afternoon Thursday after dipping 3% in after hours trade the evening prior on the news that CVS Health Corp (NYSE:CVS) announced it will remove Hu
7 Upcoming Dividend Increases, Including The 'Abbott's' And A Dividend King
12:56pm, Thursday, 04'th Jan 2024
Seven stocks are expected to increase their dividends next week, including Hormel, Mastercard, Abbott Laboratories, and AbbVie.
Abbvie shares down as CVS moves to replace top selling arthritis drug with cheaper alternatives
03:22am, Thursday, 04'th Jan 2024
Abbvie Inc (NYSE:ABBV) shares fell after hours on Wednesday after CVS Health Corp announced it will remove Humira, a leading rheumatoid arthritis medication, from some preferred drug lists for reim
AbbVie (ABBV) Rises As Market Takes a Dip: Key Facts
06:47pm, Wednesday, 03'rd Jan 2024
AbbVie (ABBV) closed the most recent trading day at $160.46, moving +0.4% from the previous trading session.
Abbvie shares tumble after CVS drops Humira in favor of biosimilars
05:38pm, Wednesday, 03'rd Jan 2024
CNBC's Bertha Coombs joins 'Fast Money' to talk Abbvie's stock sliding in extended trading after CVS announced it is dropping coverage of Humira.
CVS will remove AbbVie's Humira from some drug reimbursement lists in April
05:04pm, Wednesday, 03'rd Jan 2024
CVS Health said on Wednesday it will remove AbbVie's blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement as of April 1, and will recommend biosimil
1 Concerning Trend for AbbVie Investors to Keep an Eye On
08:30am, Wednesday, 03'rd Jan 2024
AbbVie pays a high yield of 4%, and it has been increasing its dividend for years. However, the company's latest rate hike was more modest than it has been in years past.
7 Dividend Aristocrats With Boatloads of Passive Income Potential
02:29pm, Tuesday, 02'nd Jan 2024
The current market is characterized by price volatility and return uncertainty. However, seven companies span across various sectors—consumer staples, financial, healthcare, energy, industrials and
